Prognostic factors and efficacy of human intravenous immunoglobulin G in dogs with idiopathic immune-mediated hemolytic anemia: a retrospective study

KEY FINDINGS There is conflicting evidence on the efficacy of intravenous immunoglobin G in the treatment of COVID-19 patients with severe disease. Intravenous immunoglobulin G (IVIg) is a mixture of polyclonal immunoglobulin G (IgG3, IgG4) antibodies as well as variable amounts of proteins; IgA, IgE and IgM antibodies isolated and pooled from healthy donors. IgG is involved in viral neutralization, modulates anti-inflammatory cytokines and cytokine antagonists. Immediate adverse effects of IVIg include flu-like syndrome, dermatologic side effects, arrhythmia, hypotension, and transfusion-related acute lung injury (TRALI). Delayed adverse effects can involve any organ which could be severe or even lethal There was a retrospective study (Yun Xie 2020) and several case reports that described recovery of COVID positive patients with severe disease. However, a retrospective study showed that immunoglobulin G with steroids and antivirals did not improve COVID patients with acute respiratory distress syndrome (Liu Y 2020). Similarly, another study showed no significant difference in the 28- and 60-day mortality between the IVIg and non-IVIg groups but subgroup analyses reported that in those with critical COVID illness, 28 day mortality is decreased with IVIg (Shao Z). There are eight registered clinical trials on the use of intravenous immunoglobulin G in COVID-19 patients.

Download Full-text

Comparative removal of solvent and detergent viral inactivating agents from human intravenous immunoglobulin G preparations using SDR HyperD and C18 sorbents

Analytical Biochemistry ◽

10.1016/j.ab.2009.03.016 ◽

2009 ◽

Vol 389 (1) ◽

pp. 69-73 ◽

Cited By ~ 3

Author(s):

Thierry Burnouf ◽

Makram A. Sayed ◽

Miryana Radosevich ◽

Magdy El-Ekiaby

Keyword(s):

Intravenous Immunoglobulin ◽

Immunoglobulin G ◽

Intravenous Immunoglobulin G ◽

Human Intravenous Immunoglobulin

Download Full-text

Intravenous immunoglobulin G in the treatment of ABO hemolytic disease of the newborn during the early neonatal period at a tertiary academic hospital: a retrospective study

Journal of Perinatology ◽

10.1038/s41372-021-00963-5 ◽

2021 ◽

Author(s):

Jiarong Pan ◽

Canyang Zhan ◽

Tianming Yuan ◽

Xiangxiang Chen ◽

Yanyan Ni ◽

...

Keyword(s):

Retrospective Study ◽

Intravenous Immunoglobulin ◽

Immunoglobulin G ◽

Neonatal Period ◽

Hemolytic Disease ◽

Neurological Sequelae ◽

Early Neonatal Period ◽

Significant Difference ◽

Intravenous Immunoglobulin G ◽

Abo Hemolytic Disease

Abstract Objective To evaluate the efficacy and safety of intravenous immunoglobulin G (IVIG) in infants with ABO hemolytic disease of the newborn (HDN). Methods Infants with moderate-to-severe ABO HDN during early neonatal period (<7 days) at our hospital in 2017 were included in this retrospective study. Patients treated with IVIG and phototherapy were classified as the IVIG group, and those who only received phototherapy were classified as the phototherapy only group. Results Forty-six patients were classified into the IVIG group and 68 other patients were classified into the phototherapy only group. There was no significant difference in duration of phototherapy, hospitalization periods, needs for exchange transfusion, transfusions, and incidence of bilirubin-induced neurological sequelae between these two groups (P = 0.20, 0.27, 0.65, 0.47, 0.78, respectively). Conclusion It seems unnecessary to expose neonates to IVIG in moderate-to-severe ABO HDN when the available data show no appreciable benefits.

Download Full-text